Novel Plasma-Derived IAIP Therapy
Pre-clinical- Indications
- Acute inflammatory conditions
Company intelligence / Profile preview
ProThera Biologics
East Providence, Rhode Island, United Statesprotherabiologics.com ↗
- Ownership
- Private
- Employees
- ~20
- Development stage
- Preclinical
01
Overview
ProThera has demonstrated the potential of IAIP therapy in numerous preclinical models and the use of IAIP as a biomarker in clinical samples. The company is developing both therapeutic products and diagnostic tools based on IAIP technology.
- Therapeutic areas
- GastroenterologyImmunologyCardiovascularInfectious Diseases
- Modalities
- Plasma-derived proteinsBiologics
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Takeda Pharmaceutical Company LimitedProMetic Life Sciences
Beyond the preview
Go deeper on ProThera Biologics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ProThera Biologics.